MDB Capital Holdings Provides Second Quarter 2025 Update
MDB Capital Holdings (NASDAQ: MDBH), a public venture platform, has provided its Q2 2025 operational update highlighting several key developments. The company announced a private offering for Paulex Bio, which is developing an oral diabetes medication, and filed an S-1 for Buda Juice's IPO.
Notable developments include a strategic partnership with Keiretsu Forum MST for the IPO Angels platform and plans to spin out PatentVest as an independent public company in 2026. MDB is strengthening its position in public markets while expanding relationships with RIAs to reach investors seeking venture exposure.
MDB Capital Holdings (NASDAQ: MDBH), una piattaforma pubblica di venture, ha pubblicato l'aggiornamento operativo relativo al secondo trimestre 2025 con diversi sviluppi chiave. La societ脿 ha annunciato un collocamento privato per Paulex Bio, che sta sviluppando un farmaco orale per il diabete, e ha depositato un modulo S-1 per l'IPO di Buda Juice.
Tra i punti salienti si segnala una partnership strategica con Keiretsu Forum MST per la piattaforma IPO Angels e l'intenzione di scorporare PatentVest come societ脿 pubblica indipendente nel 2026. MDB sta rafforzando la sua presenza nei mercati pubblici ampliando al contempo le relazioni con le RIA per raggiungere investitori interessati all'esposizione venture.
MDB Capital Holdings (NASDAQ: MDBH), una plataforma p煤blica de venture, present贸 su actualizaci贸n operativa del segundo trimestre de 2025 con varios avances clave. La compa帽铆a anunci贸 una oferta privada para Paulex Bio, que desarrolla un medicamento oral para la diabetes, y present贸 un S-1 para la OPI de Buda Juice.
Entre los hechos destacados figura una alianza estrat茅gica con Keiretsu Forum MST para la plataforma IPO Angels y el plan de escindir PatentVest como empresa p煤blica independiente en 2026. MDB est谩 reforzando su posici贸n en los mercados p煤blicos mientras ampl铆a las relaciones con las RIA para llegar a inversores que buscan exposici贸n a ventures.
MDB Capital Holdings (NASDAQ: MDBH)電� 瓿店皽 氩れ矘 頂岆灚韽检溂搿滌劀 2025雲� 2攵勱赴 鞖挫榿 鞐呺嵃鞚错姼毳� 氚滍憸頃橂┌ 鞐煬 欤检殧 靷晥鞚� 臧曥“頄堨姷雼堧嫟. 須岇偓電� 雼闺嚚氤� 瓴疥惮鞖� 鞎诫鞚� 臧滊皽 欷戩澑 Paulex Bio鞐� 雽�頃� 靷(頂勲澕鞚措箺 鞓ろ嵓毵�)毳� 氚滍憸頄堦碃, Buda Juice鞚� IPO毳� 鞙勴暅 S-1鞚� 鞝滌稖頄堨姷雼堧嫟.
欤检殧 雮挫毄鞙茧電� IPO Angels 頂岆灚韽检潉 鞙勴暅 Keiretsu Forum MST鞕�鞚� 鞝勲灥鞝� 韺岉姼雱堨嫮瓿� 2026雲勳棎 PatentVest毳� 霃呺霅� 靸侅灔 須岇偓搿� 攵勳偓頃� 瓿勴殟鞚� 韽暔霅╇媹雼�. MDB電� 瓿惦 鞁滌灔鞐愳劀鞚� 鞛呾毳� 臧曧檾頃橂姅 霃欖嫓鞐� RIA鞕�鞚� 甏�瓿勲ゼ 雱擁榾 氩れ矘 韴瀽 雲胳稖鞚� 彀倦姅 韴瀽鞛愲摛鞐愱矊 雼り皜臧�瓿� 鞛堨姷雼堧嫟.
MDB Capital Holdings (NASDAQ: MDBH), une plateforme publique de venture, a publi茅 sa mise 脿 jour op茅rationnelle pour le deuxi猫me trimestre 2025, mettant en avant plusieurs d茅veloppements cl茅s. La soci茅t茅 a annonc茅 une offre priv茅e pour Paulex Bio, qui d茅veloppe un m茅dicament oral contre le diab猫te, et a d茅pos茅 un S-1 pour l'introduction en bourse de Buda Juice.
Parmi les 茅l茅ments notables figurent un partenariat strat茅gique avec Keiretsu Forum MST pour la plateforme IPO Angels et l'intention de scinder PatentVest en une soci茅t茅 publique ind茅pendante en 2026. MDB renforce sa position sur les march茅s publics tout en 茅largissant ses relations avec les RIA afin d'atteindre des investisseurs cherchant une exposition aux ventures.
MDB Capital Holdings (NASDAQ: MDBH), eine 枚ffentliche Venture-Plattform, ver枚ffentlichte ihr operatives Update f眉r das zweite Quartal 2025 mit mehreren wichtigen Entwicklungen. Das Unternehmen k眉ndigte ein Privatplatzierung f眉r Paulex Bio an, das ein orales Diabetesmedikament entwickelt, und reichte ein S-1 f眉r den B枚rsengang von Buda Juice ein.
Zu den bemerkenswerten Punkten z盲hlt eine strategische Partnerschaft mit Keiretsu Forum MST f眉r die IPO Angels-Plattform sowie der Plan, PatentVest im Jahr 2026 als eigenst盲ndiges b枚rsennotiertes Unternehmen auszugliedern. MDB st盲rkt seine Position an den 枚ffentlichen M盲rkten und baut gleichzeitig die Beziehungen zu RIAs aus, um Anleger mit Venture-Exposure zu erreichen.
- Strategic expansion through partnership with Keiretsu Forum MST for IPO Angels platform
- Planned spin-out of PatentVest as independent public company in 2026
- Pipeline growth with new companies including Paulex Bio and Buda Juice
- Expanded reach to new investors through RIA relationships
- Operating in challenging venture and private equity market conditions
Insights
MDB Capital expands its public venture platform with new offerings, partnerships, and spin-out plans, positioning aggressively against traditional VC weakness.
MDB Capital Holdings is executing an interesting counter-strategy to the struggling private venture capital market. The company has made several strategic moves in Q2 2025 that strengthen its position as a public venture platform for early-stage companies with category-disruption potential.
The launch of a private offering for Paulex Bio represents a significant entry into the lucrative diabetes treatment space. Their oral medication approach targeting the root cause of diabetes, rather than just managing symptoms, could create substantial value if successful. The diabetes treatment market exceeds
Their upcoming IPO for Buda Juice demonstrates MDB's commitment to their public market thesis. The premium juice category has seen remarkable growth as health-conscious consumers seek high-quality, functional beverages. Buda's UltraFresh鈩� technology appears to be their differentiation factor in a competitive market.
The strategic partnership with Keiretsu Forum MST to drive the IPO Angels platform represents a clever approach to expanding their investor network. By broadening relationships with RIAs (Registered Investment Advisors), MDB is creating distribution channels to wealthy individual investors seeking venture exposure outside traditional private funds.
Perhaps most notable is the planned spin-out of PatentVest as an independent public company in 2026. This move will allow MDB to unlock value from their intellectual property services while maintaining strategic alignment. IP-focused legal services for emerging tech companies represent a high-margin business with recurring revenue potential.
CEO Christopher Marlett's statement that "public markets are the place to be for emerging companies" signals MDB's contrarian bet against traditional venture capital. As traditional VC firms struggle with delayed exits and down rounds, MDB is positioning itself as an alternative path to capital and liquidity for innovative companies.
Management to Host Conference Call Today at 4:30 p.m. ET
Addison, TX, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MDB Capital Holdings, LLC, (NASDAQ: MDBH)听(鈥淢DB鈥�), a public venture platform focused on launching category-leading 鈥淏ig Idea鈥� companies, today provides an operational update for the quarter ended June 30, 2025, and subsequent developments.
Second Quarter 2025 and Subsequent Operational Highlights
- Launched private offering for Paulex Bio, a company developing a transformational oral medication designed to eliminate the root cause of diabetes.
- Announced our next IPO and filed S-1 for Buda Juice, which is redefining the fresh juice category with UltraFresh鈩� cold-crafted juices.
- Deepened our pipeline of early-stage, disruptive companies capable of becoming leaders in new categories.
- Announced new strategic partnership with Keiretsu Forum MST to drive IPO Angels, a platform that will further expand MDB鈥檚 investor community.
- Broadened relationships with RIAs to reach new investors with large equity portfolios looking for new strategies to gain venture exposure.
- Announced plans to spin-out PatentVest, the 鈥渘ext generation鈥� IP law firm, as an independent public company in 2026 to further leverage this unique asset and create value for MDB.
鈥淲e鈥檙e betting that the public markets are the place to be for emerging companies as the traditional venture and private equity markets are under significant restructuring,鈥� said Christopher Marlett, CEO and Co-Founder of MDB Capital Holdings. 鈥淲e鈥檙e excited to launch more visionary companies on public markets and provide investors with additional public venture opportunities.鈥�
Second Quarter 2025 Update Zoom Webinar at 4:30 p.m. ET Today
Christopher Marlett, CEO and Co-Founder of MDB will lead the call and may be joined by other members of the management team to review recent developments, ongoing initiatives, and anticipated milestones, as well as host a question-and-answer session.
Investors can pre-register now for the Zoom webinar . The live webinar will also be accessible 聽on the day of the event through MDB鈥檚 investor relations website at聽.
About MDB Capital Holdings, LLC
Founded in 1997, MDB Capital focuses on launching "Big Ideas" into valuable public companies with a better approach to public venture capital. This approach leverages community-driven financings of early-stage emerging leaders in meaningful business and technology categories via early public offerings, primarily listed on NASDAQ, as well as post-IPO offerings for companies that align with MDB's overall investment criteria.
MDB Capital is the brand under which MDB Capital Holdings, LLC (NASDAQ: MDBH) and its subsidiaries operate. Its subsidiaries includes MDB Capital, a venture-focused broker-dealer with MDB Direct trading platform, and PatentVest, the first integrated IP strategy and law firm dedicated to transforming innovation into market value. MDB Capital is a registered broker-dealer, Member FINRA/SIPC.
For more information, please visit聽.
Forward-Looking Statements
This press release contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as "expect," "anticipate," "should," "believe," "hope," "target," "project," "goals," "estimate," "potential," "predict," "may," "will," "might," "could," "intend," "shall" and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements.
Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond MDB's control. MDB's actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in documents that may be filed by MDB from time to time with the SEC. The forward-looking statements included in this press release represent MDB's views as of the date of this press release. MDB anticipates that subsequent events and developments will cause its views to change. MDB undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing MDB's views as of any date subsequent to the date of this press release.
Investor Relations Contact:
Media Contact:
FAQ
What are the key developments in MDB Capital Holdings' (MDBH) Q2 2025 update?
When will MDB Capital Holdings (MDBH) spin out PatentVest?
What is the strategic partnership between MDB Capital Holdings and Keiretsu Forum MST?
What companies are in MDB Capital Holdings' current pipeline?
How can investors access MDB Capital Holdings' Q2 2025 update call?
